Price (delayed)
$215.305
Market cap
$4.28B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$19.99
Enterprise value
$4.3B
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum
There are no recent dividends present for MDGL.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.